"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
| Descriptor ID |
D010880
|
| MeSH Number(s) |
D03.383.621
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in this website by year, and whether "Piperidines" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 2 | 4 |
| 1996 | 5 | 3 | 8 |
| 1997 | 4 | 8 | 12 |
| 1998 | 4 | 9 | 13 |
| 1999 | 7 | 9 | 16 |
| 2000 | 2 | 10 | 12 |
| 2001 | 4 | 10 | 14 |
| 2002 | 9 | 10 | 19 |
| 2003 | 11 | 16 | 27 |
| 2004 | 13 | 7 | 20 |
| 2005 | 16 | 10 | 26 |
| 2006 | 13 | 18 | 31 |
| 2007 | 17 | 13 | 30 |
| 2008 | 12 | 16 | 28 |
| 2009 | 14 | 12 | 26 |
| 2010 | 14 | 18 | 32 |
| 2011 | 14 | 22 | 36 |
| 2012 | 23 | 19 | 42 |
| 2013 | 18 | 21 | 39 |
| 2014 | 21 | 18 | 39 |
| 2015 | 21 | 26 | 47 |
| 2016 | 24 | 28 | 52 |
| 2017 | 25 | 30 | 55 |
| 2018 | 20 | 31 | 51 |
| 2019 | 26 | 34 | 60 |
| 2020 | 24 | 30 | 54 |
| 2021 | 24 | 20 | 44 |
| 2022 | 3 | 23 | 26 |
| 2023 | 2 | 11 | 13 |
| 2024 | 18 | 8 | 26 |
Below are the most recent publications written about "Piperidines" by people in Profiles.
-
Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Rheumatology (Oxford). 2024 11 01; 63(11):3033-3041.
-
Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1907-1910.
-
JAK inhibition in Down Syndrome Regression Disorder. J Neuroimmunol. 2024 Oct 15; 395:578442.
-
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons. Adv Ther. 2024 Oct; 41(10):3832-3849.
-
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials. J Rheumatol. 2024 Aug 01; 51(8):772-780.
-
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC). J Clin Oncol. 2024 Oct 20; 42(30):3606-3617.
-
ALINA: Another stepping stone toward a future of LDCT lung cancer screening in never-smokers? Med. 2024 Jul 12; 5(7):649-651.
-
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024 Sep 05; 187(18):4905-4925.e24.
-
Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy. Curr Med Res Opin. 2024 Aug; 40(8):1369-1378.
-
Picaridin: A safe and effective alternative insect repellent to N, N-diethyl-meta-toluamide. Pediatr Dermatol. 2024 Jul-Aug; 41(4):763.